New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds

HORIBA (Kyoto, Japan) has expanded its line of compact hematology analyzers by introducing new models that incorporate Erythrocyte Sedimentation Rate (ESR) measurement capabilities. The newly launched Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) now deliver combined results for complete blood count (CBC)/differential (DIFF) and ESR from whole blood in just 60 seconds. This integration provides a more comprehensive assessment of inflammatory diseases, adding significant value to the instruments' existing extensive functionalities.

The integration of ESR into its three new analyzers has been made possible through HORIBA's innovative CoRA (Correlated Rouleaux Analysis) technology. By combining CBC and 5-population white blood cell DIFF with rapid ESR, calibrated to the Westergren reference method, these compact analyzers can reduce both costs per test and turnaround times, while also saving laboratory space. Additionally, both the Yumizen H550E and H500E models feature enhanced connectivity for data management through HORIBA’s Yumizen P8000 middleware and Yumicare, a remote technical support tool that ensures secure connections to the instruments for monitoring workload, reagent consumption, quality control, and instrument alarms.

The evolution of the Yumizen H550 range has also seen the inclusion of i-DoubleDiff technologies, which utilize artificial intelligence (AI) to provide score flags for infectious diseases such as malaria and dengue fever. This feature enhances the diagnostic speed and expands the utility of the analyzers in diverse medical environments, including both advanced and resource-limited settings. DoubleDiff technology further supports the addition of Normal leucocyte count (Lymphocyte, Monocyte, Neutrophil, Eosinophil, Basophil) + Abnormal leucocyte count (IMG, IMM, IML, LIC, ALY). With just two reagents, this technology has expanded the analytical capabilities of the analyzers from 27 to 37 parameters, offering deeper insights and more comprehensive results, especially in oncology. Thanks to its advanced technologies, affordability, reliability, and simplicity, the Yumizen H550 range is well-suited for a variety of clinical settings, including critical care, oncology, infectious disease management, blood banks, satellite laboratories, and health centers.

“Building on the global success of our previous Yumizen H550 range, we have designed the new analyzers to meet the increasing demand for affordable, robust, and highly capable hematology analyzers with connectivity that are suitable for any lab environment,” said Arnaud Pradel, President, HORIBA ABX SAS. “It is one instrument with endless possibilities, and the capabilities of our Yumizen H550 range continue to grow to meet even more clinical lab needs.”

Related Links:
HORIBA

Visit expo >

Gold Member

Fully Automated Cell Density/Viability Analyzer

BioProfile FAST CDV

Verification Panels for Assay Development & QC
Seroconversion Panels

New

TRAb Immunoassay

Chorus TRAb

New

Isothermal Amplification Technology

SIBA